Navigation Links
New Hope For Patients With Relapsing Multiple Sclerosis

Over two million people worldwide are estimated to suffer from multiple sclerosis (MS), which is the leading cause of neurological disability in young adults, and has a significant impact on the overall quality of life. // Currently marketed therapies afford an average reduction in relapse rates of 30% in two-year studies and require frequent injections ranging from daily to weekly.

Data from the extension of a Phase II study to 12 months conducted by Novartis Pharma confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing MS. The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that patient groups taking FTY720 who had experienced a reduction in their annualized relapse rate of more than 50% during the first 6 months of the study compared to placebo maintained this low relapse rate during the subsequent 6-month extension. More than 80% patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose.

In a press release, chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland said "We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the 6-month placebo-controlled phase of the study. FTY720 appeared to be well tolerated; there were no complications during the extension as compared to the 6-month placebo-controlled phase.

According to the press release, oral FTY720 has a novel mode of action different from all available therapies. It reversibly sequesters lymphocytes away from blood and susceptible target organs such as the central nervous system (CNS), thereby reducing neuroinflammation in MS. FTY720 has been developed b y Novartis Pharma and licensed from Mitsubishi Pharma Corporation.

Based on the positive results of the Phase II study conducted at 32 centers in 11 countries (Europe and Canada), Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Agenovir Corporation, a company ... antiviral therapeutics, today announced that it appointed ... and a member of the board of directors. ... with a deep background in both founding and ... of Agenovir, co-president of Chan Zuckerberg  Biohub ...
(Date:12/8/2016)... NORWALK, Conn. , Dec. 8, 2016   Mederi Therapeutics Inc . has ... for Stretta Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun ... , , "We ...
(Date:12/8/2016)... ANTONIO , Dec. 8, 2016 Eli ... announced that the neoMONARCH study of abemaciclib, a cyclin-dependent ... primary endpoint of reducing expression of Ki67, a biomarker ... data from the Phase 2 trial presented during the ... Cancer Symposium (SABCS) evaluated abemaciclib, both alone or in ...
Breaking Medicine Technology: